<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Palonosetron: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Palonosetron: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Palonosetron: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11422" href="/d/html/11422.html" rel="external">see "Palonosetron: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12965" href="/d/html/12965.html" rel="external">see "Palonosetron: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F14877561"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Aloxi [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867825"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Aloxi</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F205861"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiemetic;</li>
<li>
                        Selective 5-HT<sub>3</sub> Receptor Antagonist</li></ul></div>
<div class="block doa drugH1Div" id="F205844"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="170299cf-a590-4ce2-b509-66903788defc">Chemotherapy-induced nausea and vomiting, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chemotherapy-induced nausea and vomiting, prevention (moderately and highly emetogenic chemotherapy):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 0.25 mg as a single dose beginning ~30 minutes prior to the start of chemotherapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Capsule [Canadian product]: Moderately emetogenic chemotherapy: <b>Oral:</b> 0.5 mg ~1 hour prior to the start of chemotherapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Guideline recommendations: </i></b>
<b>Prevention of chemotherapy-induced nausea and vomiting: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>American Society of Clinical Oncology</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">High emetic risk, including most anthracyclines combined with cyclophosphamide regimens; antiemetic regimen also includes dexamethasone (days 1 to 4), an NK<sub>1</sub> receptor antagonist, and olanzapine (days 1 to 4):</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV:</b> 0.25 mg on day 1 prior to chemotherapy.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral:</b> 0.5 mg [Canadian product] on day 1 prior to chemotherapy.</p>
<p style="text-indent:-2em;margin-left:8em;">Moderate emetic risk; antiemetic regimen also includes dexamethasone (days 1 to 3) [and an NK<sub>1</sub> receptor antagonist for carboplatin doses of AUC ≥4]:</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV:</b> 0.25 mg on day 1 prior to chemotherapy.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral:</b> 0.5 mg [Canadian product] on day 1 prior to chemotherapy.</p>
<p style="text-indent:-2em;margin-left:8em;">Low emetic risk:</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV:</b> 0.25 mg prior to chemotherapy.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral:</b> 0.5 mg [Canadian product] prior to chemotherapy.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ae1bcfa5-9563-4c6b-a1af-01aa4e2e9d9d">Postoperative nausea and vomiting, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postoperative nausea and vomiting, prevention:</b>
<b>IV:</b> 0.075 mg as a single dose immediately prior to anesthesia induction.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991421"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment is necessary.</p></div>
<div class="block doha drugH1Div" id="F50988670"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment is necessary.</p></div>
<div class="block dot drugH1Div" id="F57435855"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity reactions: Discontinue palonosetron and manage appropriately; do not reinitiate in patients who have previously experienced hypersensitivity symptoms.</p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin syndrome: Discontinue palonosetron and begin supportive management.</p></div>
<div class="block doe drugH1Div" id="F205845"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary. Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F25120798"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12965" href="/d/html/12965.html" rel="external">see "Palonosetron: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note: </b> Dosing presented in both mcg and mg; use extra caution to verify correct units</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="170299cf-a590-4ce2-b509-66903788defc">Chemotherapy-induced nausea and vomiting, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chemotherapy-induced nausea and vomiting, prevention: Note:</b> Use in combination with or without dexamethasone and aprepitant depending upon patient age, chemotherapy emetogenic potential, and drug-interaction profile (refer to specific protocols or guidelines) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28453189']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28453189'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents &lt;17 years: IV: 20 <b>mcg</b>/kg as a single dose administered ~30 minutes prior to the start of chemotherapy; maximum dose: 1,500 <b>mcg</b>/dose (1.5 mg/dose)</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥17 years:</p>
<p style="text-indent:-2em;margin-left:6em;">IV: 0.25 mg as a single dose administered ~30 minutes before chemotherapy</p>
<p style="text-indent:-2em;margin-left:6em;">Oral [Canadian product]: Limited data available: 0.5 mg as a single dose administered prior to chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28453189']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28453189'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ae1bcfa5-9563-4c6b-a1af-01aa4e2e9d9d">Postoperative nausea and vomiting, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postoperative nausea and vomiting (PONV), prevention:</b>
<b> Note:</b> Expert recommendations for PONV management do not include palonosetron as a therapeutic option for the prevention or treatment of PONV in pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24356162']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24356162'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents &lt;17 years: Limited data available; efficacy results variable: IV: 1 <b>mcg</b>/kg as a single dose; maximum dose: 75 <b>mcg</b>/dose (0.075 mg/dose) immediately prior to anesthesia induction; dosing based on a double-blind randomized comparative trial with ondansetron which showed complete response in 78.2% of the palonosetron group and 82.7% of the ondansetron; however, palonosetron efficacy data did not meet noninferiority margin; safety analysis showed no unexpected adverse effects, similar data as adult patients.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥17 years: Limited data available in 17 years of age: IV: 0.075 mg immediately prior to anesthesia induction</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51151406"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: No dosage adjustment is necessary.</p></div>
<div class="block dohp drugH1Div" id="F51151407"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: No dosage adjustment is necessary.</p></div>
<div class="block adr drugH1Div" id="F205817"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">Frequencies reported for both indications (chemotherapy-associated nausea and vomiting and postoperative nausea and vomiting) and in adults unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (chemotherapy-associated: ≤1%; PONV: ≤1% to 4%), hypotension (≤1%), prolonged QT interval on ECG (chemotherapy-associated: ≤1%; PONV: ≤1% to 5%), sinus bradycardia (PONV: ≤1%), tachycardia (may be nonsustained; ≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (PONV: ≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperkalemia (chemotherapy-associated: ≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (chemotherapy-associated: 5%; PONV: 2%), diarrhea (≤1%), flatulence (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary retention (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (≤1%; may be transient), increased serum aspartate aminotransferase (≤1%; may be transient)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (chemotherapy-associated: ≤1%), dizziness (adults ≤1%; infants, children, adolescents &lt;1%), headache (chemotherapy-associated: adults 3% to 9%; infants, children, and adolescents &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (chemotherapy-associated: ≤1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abdominal pain, allergic dermatitis, amblyopia, anaphylactic shock, anaphylaxis, anemia, anorexia, arthralgia, cardiac arrhythmia, chills, decreased appetite, decreased gastrointestinal motility, decreased platelet count, dermatological disease (infants, children, and adolescents), distended vein, drowsiness, dyskinesia (infants, children, and adolescents), dyspepsia, electrolyte disturbance, epistaxis, euphoria, extrasystoles, eye irritation, fatigue, fever, flattened T wave on ECG, flu-like symptoms, glycosuria, hiccups, hot flash, hyperglycemia, hypersensitivity reaction (including bronchospasm, dyspnea, edema, erythema of skin, swelling, urticaria), hypersomnia, hypertension, hypokalemia, hypoventilation, increased bilirubin (transient), increased liver enzymes, infusion site pain (infants, children, and adolescents), injection site reaction (includes burning sensation at injection site, discomfort at injection site, induration at injection site, pain at injection site), insomnia, ischemic heart disease, laryngospasm, limb pain, metabolic acidosis, motion sickness, paresthesia, serotonin syndrome, sialorrhea, sinoatrial nodal rhythm disorder, sinus tachycardia, skin rash, supraventricular extrasystole, tinnitus, vein discoloration, ventricular premature contractions, xerostomia</p></div>
<div class="block coi drugH1Div" id="F205829"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Known hypersensitivity to palonosetron or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F205815"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• ECG effects: Selective 5-HT<sub>3</sub> receptor antagonists have been associated with dose-dependent increases in ECG intervals (eg, PR, QRS duration, QT/QTc, JT). At doses of 9 times the maximum recommended adult dose, palonosetron does not prolong the QT interval to any clinically relevant extent. A thorough QT/QTc study evaluating the effect of palonosetron on QT/QTc demonstrated a magnitude of effect less than the threshold for regulatory concern (Morganroth 2016). Reduction in heart rate may occur with the 5-HT<sub>3</sub> antagonists, including palonosetron (Gonullu 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions (including anaphylaxis and anaphylactic shock) have been reported in patients with or without known hypersensitivity to other 5-HT<sub>3</sub> receptor antagonists.</p>
<p style="text-indent:-2em;margin-left:4em;">• Serotonin syndrome: Serotonin syndrome (SS) has been reported with 5-HT<sub>3</sub> receptor antagonists, predominantly when used in combination with other serotonergic agents (eg, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and/or methylene blue). Some of the cases have been fatal. The majority of SS reports due to 5-HT<sub>3</sub> receptor antagonists have occurred in a post-anesthesia setting or in an infusion center. SS has also been reported following overdose of another 5-HT<sub>3</sub> receptor antagonist. Signs of SS include mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile BP, diaphoresis, dizziness, flushing, hyperthermia); neuromuscular changes (eg, tremor, rigidity, myoclonus, hyperreflexia, incoordination); GI symptoms (eg, nausea, vomiting, diarrhea); and/or seizures.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Chemotherapy-associated emesis: Antiemetics are most effective when used prophylactically (MASCC/ESMO [Roila 2016]). If emesis occurs despite optimal antiemetic prophylaxis, reevaluate emetic risk, disease status, concurrent morbidities, and current medications to assure antiemetic regimen is optimized (ASCO [Hesketh 2020]).</p></div>
<div class="block foc drugH1Div" id="F205824"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aloxi: 0.25 mg/5 mL (5 mL [DSC]) [contains edetate (edta) disodium dihydrate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.25 mg/5 mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aloxi: 0.25 mg/5 mL (5 mL [DSC]) [contains edetate (edta) disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.25 mg/2 mL (2 mL); 0.25 mg/5 mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.25 mg/5 mL (5 mL)</p></div>
<div class="block geq drugH1Div" id="F205812"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F5062442"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Palonosetron HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25 mg/2 mL (per mL): $24.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25 mg/5 mL (per mL): $1.44 - $74.69</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Palonosetron HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25 mg/5 mL (per mL): $12.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867826"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aloxi: 0.5 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aloxi: 0.25 mg/5 mL (5 mL) [contains edetate (edta) disodium]</p></div>
<div class="block adm drugH1Div" id="F205826"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Flush IV line with NS prior to and following palonosetron administration. Do not mix with other medications.</p>
<p style="text-indent:-2em;margin-left:2em;">Prevention of chemotherapy-induced nausea and vomiting: Infuse over 30 seconds, beginning ~30 minutes prior to the start of chemotherapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Capsule [Canadian product]: Administer ~1 hour prior to the start of chemotherapy. May be administered with or without food.</p>
<p style="text-indent:-2em;margin-left:2em;">Prevention of postoperative nausea and vomiting: Infuse over 10 seconds immediately prior to anesthesia induction.</p></div>
<div class="block admp drugH1Div" id="F52613511"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Flush IV line with NS prior to and following administration. Do not use the prefilled syringe for doses &lt;0.25 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Prevention of chemotherapy-induced nausea and vomiting:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents &lt;17 years: May administer IV undiluted or further dilute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15328393']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15328393'])">Ref</a></span>) and infuse over 15 minutes, beginning ~30 minutes prior to the start of chemotherapy</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥17 years: Administer IV undiluted, infuse over 30 seconds, beginning ~30 minutes prior to the start of chemotherapy</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Prevention of postoperative nausea and vomiting:</b> May administer IV undiluted and infuse over 10 seconds immediately prior to anesthesia induction</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Capsule [Canadian product]: May be administered with or without food.</p></div>
<div class="block use drugH1Div" id="F205825"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chemotherapy-induced nausea and vomiting:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses in adults treated with moderately emetogenic cancer chemotherapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Prevention of acute nausea and vomiting associated with initial and repeat courses in adults treated with highly emetogenic cancer chemotherapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy (including highly emetogenic chemotherapy) in pediatric patients 1 month to &lt;17 years of age.</p>
<p style="text-indent:-2em;margin-left:4em;">Capsules [Canadian product]: Prevention of acute nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Postoperative nausea and vomiting:</b> Prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery in adults (efficacy beyond 24 hours has not been demonstrated).</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Routine prophylaxis for PONV in patients with minimal expectation of nausea and/or vomiting is not recommended, although palonosetron is recommended in patients when nausea and vomiting must be avoided in the postoperative period, even if the incidence of PONV is low.</p></div>
<div class="block mst drugH1Div" id="F205868"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aloxi may be confused with Eloxatin, oxaliplatin</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Palonosetron may be confused with dolasetron, granisetron, ondansetron</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F205854"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F205819"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Apomorphine: Antiemetics (5HT3 Antagonists) may enhance the hypotensive effect of Apomorphine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): Antiemetics (5HT3 Antagonists) may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: Antiemetics (5HT3 Antagonists) may enhance the serotonergic effect of TraMADol.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F205831"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Information related to use of palonestron for the prevention of postoperative nausea and vomiting in patients undergoing cesarean delivery has been evaluated (Swaro 2018).</p></div>
<div class="block brc drugH1Div" id="F205832"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if palonosetron is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, the benefits of treatment to the mother, and the underlying maternal condition.</p></div>
<div class="block mop drugH1Div" id="F57435856"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for signs/symptoms of hypersensitivity and serotonin syndrome.</p></div>
<div class="block pha drugH1Div" id="F205814"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Palonosetron is a selective 5-HT<sub>3</sub> receptor antagonist, blocking serotonin, both on vagal nerve terminals in the periphery and centrally in the chemoreceptor trigger zone.</p></div>
<div class="block phk drugH1Div" id="F205828"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Capsules [Canadian product]: Well absorbed.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 1 month to 17 years: Mean range: 5.3 to 6.3 L/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 8.3 ± 2.5 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~62%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: ~50% metabolized via CYP enzymes (and likely other pathways) to relatively inactive metabolites (N-oxide-palonosetron and 6-S-hydroxy-palonosetron); CYP1A2, 2D6, and 3A4 contribute to its metabolism.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Capsules [Canadian product]: 97%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: IV: Children 1 month to 17 years: Median: 29.5 hours (range: 20 to 30 hours); Adults: ~40 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak (plasma): Capsules [Canadian product]: 5.1 ± 5.9 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~80%; ~40% as unchanged drug).</p>
<p style="text-indent:-2em;margin-left:2em;">Clearance:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and children &lt;2 years: 0.31 L/hour/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to &lt;12 years: Mean range: 0.19 to 0.23 L/hour/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years, Adolescents, and Adults: 0.16 L/hour/kg.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539911"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Aloxi</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Palonosetron accord</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Palonoset | Palonosetron dr reddys</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Palnox | Paloron | Paloset | Palosis | Palostar | Palostat | Palotic | Paloxi | Paloxiron | Panoset | Patron | Vomiren</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Palonosetron accord | Palonosetron fresenius kabi | Palonosetron sandoz</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Ferant | Palonosetron accord | Palonosetron sandoz</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Onicit | Palocyt</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Palonosetron accord | Palonosetron sandoz | Palonosetron teva</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ruo shan</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Onicit | Palocip | Palonosetron</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Ferant | Palonosetron accord | Palonosetron fresenius kabi | Palonosetron sandoz</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Palonosetron | Palonosetron accord | Palonosetron beta | Palonosetron fresenius kabi | Palonosetron hikma | Palonosetron inresa | Palonosetron onkovis | Palonosetron stada</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Onicit</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Palonosetron accord</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Nausetron | Navesetron</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Palonosetron accord | Palonosetron Altan | Palonosetron sala</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Palonosetron accord | Palonosetron macure | Palonosetron reig jofre | Palonosetron stada</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Palonosetron accord</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Palonosetron</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Ferant | Palonosetron accord</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Aloxi</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Palonosetron accord</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Palonosetron accord | Palonosetron onkogen</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Palofer | Paloxi</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Palonosetron | Palonosetron accord</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Chepatron | Instantino | Palnox | Palostar | Palotron | Palozac | Palzen | Pasetron | Planoset | Themiset</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Palonosetron accord | Palonosetron dr. reddy's | Palonosetron fresenius kabi | Palonosetron hikma | Palonosetron teva</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Aloxi</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Palonosetron | Palonosetron np | Palonosetron towa</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Themiset</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aloctron | Aloxi | Palonon | Palonoxi | Paloset | Paloxi | Palseron | Panitron | Penmix palonosetron hydrochloride | Pharmsetron | Samsung palonosetron | Teva palonosetron | Yoosetron</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Votron</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Aloxi</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Ferant | Palonosetron accord</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Aloxi</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Ferant | Palonosetron | Palonosetron accord | Palonosetron sandoz</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Bogasen | Odecatrenol | Onicit | Palonosetron | Vinaltro | Viqet</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Palset</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Aloxi</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Palonosetron | Palonosetron accord</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Onicit | Palohalt</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Palonosetron HCL</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Palonosetron accord</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Palonosetron | Palonosetron HCL</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Aloxi</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Aloxi</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Ferant | Palonosetron accord | Palonosetron alvogen | Palonosetron dr reddys | Palonosetron fresenius kabi | Palonosetron sandoz | Palonosetron teva</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Onicit | Onycit</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Seronorm</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Palonosetron accord | Palonosetron fresenius kabi | Palonosetron kalceks | Palonosetron reig jofre | Palonosetron stada</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Aloxi</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Palonosetron accord | Palonosetron sandoz | Palonosetron stada</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Ferant | Palonosetron accord | Palonosetron fresenius kabi</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Palset</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Cinvex | Dekol | Emtron | Lotisa | Palodin | Paloject | Palondem | Palonex | Paloxitron | Palsel | Polisetron | Vomiset | Vonaxi | Votron</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Aloxi | Palonosetron | Stothu</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Onicit | Palonosetron ascendis | Tronson</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-16766588">
<a name="16766588"></a>Aapro MS, Grunberg SM, Manikhas GM, et al, “A Phase III, Double-Blind, Randomized Trial of Palonosetron Compared With Ondansetron in Preventing Chemotherapy-Induced Nausea and Vomiting Following Highly Emetogenic Chemotherapy,” <i>Ann Oncol</i>, 2006, 17(9):1441-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palonosetron-drug-information/abstract-text/16766588/pubmed" id="16766588" target="_blank">16766588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aloxi.1">
<a name="Aloxi.1"></a>Aloxi (palonosetron) [prescribing information]. Iselin, NJ: Helsinn Therapeutics (US) Inc; April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aloxi.2">
<a name="Aloxi.2"></a>Aloxi (palonosetron) [product monograph]. Montreal, Quebec, Canada: Knight Therapeutics Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24356162">
<a name="24356162"></a>Gan TJ, Diemunsch P, Habib AS, et al. Consensus guidelines for the management of postoperative nausea and vomiting [published corrections appear in <i>Anesth Analg</i>. 2015;120(2):494 and <i>Anesth Analg</i>. 2014;118(3):689]. <i>Anesth Analg</i>. 2014;118(1):85-113.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palonosetron-drug-information/abstract-text/24356162/pubmed" id="24356162" target="_blank">24356162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21773677">
<a name="21773677"></a>Gonullu G, Demircan S, Demirag MK, et al. Electrocardiographic findings of palonosetron in cancer patients. <i>Support Care Cancer</i>. 2012;20(7):1435-1439.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palonosetron-drug-information/abstract-text/21773677/pubmed" id="21773677" target="_blank">21773677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14504060">
<a name="14504060"></a>Gralla R, Lichinister M, Van Der Vegt S, et al, “Palonosetron Improves Prevention of Chemotherapy-Induced Nausea and Vomiting Following Moderately Emetogenic Chemotherapy: Results of a Double-Blind Randomized Phase III Trial Comparing Single Doses of Palonosetron With Ondansetron,” <i>Ann Oncol</i>, 2003, 14(10):1570-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palonosetron-drug-information/abstract-text/14504060/pubmed" id="14504060" target="_blank">14504060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. <i>J Clin Oncol</i>. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palonosetron-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18769000">
<a name="18769000"></a>Kupiec TC, Trusley C, Ben M, et al, “Physical and Chemical Stability of Palonosetron Hydrochloride With Five Common Parenteral Drugs During Simulated Y-Site Administration,” <i>Am J Health-Syst Pharm</i>, 2008, 65(18):1735-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palonosetron-drug-information/abstract-text/18769000/pubmed" id="18769000" target="_blank">18769000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26111957">
<a name="26111957"></a>Morganroth J, Flaharty KK, Parisi S, et al. Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteers. <i>Support Care Cancer</i>. 2016;24(2):621-627.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palonosetron-drug-information/abstract-text/26111957/pubmed" id="26111957" target="_blank">26111957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Morganroth.2007">
<a name="Morganroth.2007"></a>Morganroth L, Parisi S, Spinelli T, et al. High dose palonosetron does not alter ECG parameters including QTc interval in healthy subjects: results of a dose-response, double-blind, randomized, parallel E14 study of palonosetron vs. moxifloxacin or placebo. Presented at the 14th European Conference of Clinical Oncology (ECCO), September 2007; Barcelona, Spain.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fresenius.1">
<a name="Fresenius.1"></a>Palonosetron hydrochloride [prescribing information]. Lake Zurich, IL: Fresenius Kabi; June 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28453189">
<a name="28453189"></a>Patel P, Robinson PD, Thackray J, et al. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update [published online April 28, 2017]. <i>Pediatr Blood Cancer</i>. 2017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palonosetron-drug-information/abstract-text/28453189/pubmed" id="28453189" target="_blank">28453189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27664248">
<a name="27664248"></a>Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(Suppl 5):S119-S133.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palonosetron-drug-information/abstract-text/27664248/pubmed" id="27664248" target="_blank">27664248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29962591">
<a name="29962591"></a>Swaro S, Karan D, Banerjee A. Comparison of palonosetron, dexamethasone, and palonosetron plus dexamethasone as prophylactic antiemetic and antipruritic drug in patients receiving intrathecal morphine for lower segment cesarean section. <i>Anesth Essays Res</i>. 2018;12(2):322-327. doi:10.4103/aer.AER_183_17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palonosetron-drug-information/abstract-text/29962591/pubmed" id="29962591" target="_blank">29962591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9706951">
<a name="9706951"></a>Tang J, D'Angelo R, White PF, et al, “The Efficacy of RS-25259, A Long-Acting Selective 5-HT<sub>3</sub> Receptor Antagonist, for Preventing Postoperative Nausea and Vomiting After Hysterectomy Procedures,” <i>Anesth Analg</i>, 1998, 87(2):462-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palonosetron-drug-information/abstract-text/9706951/pubmed" id="9706951" target="_blank">9706951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15328393">
<a name="15328393"></a>Trissel LA and Xu QA, “Physical and Chemical Stability of Palonosetron HCl in 4 Infusion Solutions,” <i>Ann Pharmacother</i>, 2004, 38(10):1608-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palonosetron-drug-information/abstract-text/15328393/pubmed" id="15328393" target="_blank">15328393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19139929">
<a name="19139929"></a>Zambelli A, Sagrada P, and Pavesi L, “Seizure Associated With Palonosetron,” <i>Support Care Cancer</i>, 2009, 17(3):217.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palonosetron-drug-information/abstract-text/19139929/pubmed" id="19139929" target="_blank">19139929</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9944 Version 271.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
